Ryzodeg FlexTouch

Ryzodeg FlexTouch

Manufacturer:

Novo Nordisk

Distributor:

Novo Nordisk
Concise Prescribing Info
Contents
Per mL soln for inj 100 u of insulin degludec/insulin aspart in the ration 70/30 (equiv to insulin degludec 2.56 mg, insulin aspart 1.05 mg)
Indications/Uses
DM in adults, adolescents & childn from the age of 2 yr.
Dosage/Direction for Use
Individualized dose. Type 2 DM Initially 10 u. Patient w/ type 2 DM: Switching from once-daily basal or premix insulin therapy The same total insulin dose once-daily as the patient's previous total daily insulin. Switching from more than once-daily basal or premix insulin therapy The same total insulin dose bid as the patient's previous total daily insulin dose. Switching from basal/bolus insulin therapy to Ryzodeg Individualized dosage. Type 1 DM Initially 60-70% of the total daily insulin requirements. Transfer from other insulin products Doses & timing of concurrent rapid- or short-acting insulin products or other antidiabetic treatment may need to be adjusted. Ped patient Transfer from other insulin products. Dose reduction of total insulin needs to be considered on an individual basis in order.
Administration
Should be taken with food: OD: Taken w/ the largest meal. BID: Taken w/ main meals.
Special Precautions
Hypoglycemia or hyperglycemia; diabetic retinopathy; lipodystrophy may occur. May form insulin Ab(s). Transfer from other insulin medicinal products. Concomitant use w/ thiazolidinediones. Do not administer IV/IM. May impair ability to drive & use of machinery. There is no clinical experience with the use of pregnancy & lactation. Use w/ special caution in childn 2-5 yr because clinical trial data indicate there may be a higher risk for severe hypoglycemia in childn. Extra care should be taken to match insulin doses w/ food intake & physical activities in order to minimize risk of hypoglycemia.
Adverse Reactions
Hypoglycaemia; inj site reactions; peripheral edema; hypersensitivity; urticaria.
Drug Interactions
Reduced insulin requirement w/ oral antidiabetics eg, GLP-1 receptor agonists, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulfonamides. Increased insulin requirement w/ OCs, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. May mask symptoms of hypoglycaemia w/ β-blockers. Increased/decreased insulin requirement w/ octreotide/lanreotide. Intensified/reduced hypoglycemic effect w/ alcohol.
MIMS Class
Insulin Preparations
ATC Classification
A10AD06 - insulin degludec and insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Ryzodeg FlexTouch soln for inj 100 u/mL
Packing/Price
3 mL x 5 × 1's (P5,765/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in